GLP1R and type 2 diabetes mellitus: The recent generation of glucose-lowering agents, exemplified by glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), has found application in numerous patients to achieve a significant weight reduction, glycemic control in T2D, and mitigation of cardiovascular risk [[5], [6], [7]].